Sulfasalazine in Pregnancy
Sulfasalazine can be safely continued throughout pregnancy at doses up to 2 g/day, but you must prescribe concomitant folic acid supplementation at 2 mg daily (or 5 mg daily for higher-risk patients) to prevent neural tube defects. 1
Safety Profile
The most recent 2025 EULAR guidelines explicitly list sulfasalazine as a pregnancy-compatible disease-modifying antirheumatic drug that should be continued for maintenance of remission 1. Current evidence does not indicate an increased rate of congenital malformations or adverse pregnancy outcomes when used appropriately.
The 2025 IBD global consensus statement confirms no increased risk of congenital abnormalities with sulfasalazine exposure (adjusted OR 1.2; 95% CI, 0.6–2.1) 2. The FDA label classifies sulfasalazine as Pregnancy Category B, with animal studies showing no harm at doses up to 6 times the human maintenance dose 3.
Critical Management Requirements
Folic Acid Supplementation (Non-Negotiable)
- Standard dose: 2 mg daily 1
- High-risk dose: 5 mg daily for women with additional risk factors 4
- Start before conception and continue throughout pregnancy
Why this matters: Sulfasalazine inhibits folate absorption and metabolism through its sulfapyridine moiety 2, 3. This antifolate effect can diminish the protective effect of periconceptional folic acid supplementation against neural tube defects 3. A 2026 case report documented spina bifida and ventriculomegaly in a fetus after maternal sulfasalazine exposure without folic acid supplementation 4. While causality cannot be definitively established, this represents a preventable risk.
Dosing Limits
- Maximum dose: 2 g/day during pregnancy 1
- If higher doses are needed for disease control, consider switching to alternative 5-ASA agents 2
Monitoring Protocol
Per FDA labeling 3:
- Before starting: Complete blood count with differential, liver function tests
- First 3 months: CBC and LFTs every 2 weeks
- Months 4-6: Monthly CBC and LFTs
- After 6 months: Every 3 months and as clinically indicated
- Throughout: Periodic urinalysis and renal function assessment
Monitor serum sulfapyridine levels if available; concentrations >50 mcg/mL are associated with increased adverse reactions 3.
Disease-Specific Considerations
For Ulcerative Colitis
Maintaining disease remission is critical—disease flares pose greater risk to pregnancy outcomes than continued sulfasalazine therapy 2. Nearly 25% of previously adherent IBD patients discontinue therapy during pregnancy, leading to preventable flares 2. Do not discontinue sulfasalazine in pregnant UC patients with well-controlled disease.
For Rheumatoid Arthritis
Active RA disease and high-dose glucocorticoids are associated with poor fertility and adverse pregnancy outcomes 5. Sulfasalazine provides a safer alternative to methotrexate (which is absolutely contraindicated) and reduces the need for higher glucocorticoid doses 1.
Common Pitfalls to Avoid
Discontinuing therapy due to pregnancy: This is the most common error. Untreated maternal disease carries greater risk than continued sulfasalazine therapy 1
Forgetting folic acid supplementation: This is the single most important modifiable risk factor. The 2026 neural tube defect case occurred specifically in the absence of folate supplementation 4
Using inadequate folate doses: Standard prenatal vitamins (0.4-0.8 mg) are insufficient. Prescribe 2-5 mg daily 1, 4
Failing to counsel about kernicterus risk: Sulfasalazine and sulfapyridine cross the placenta and are present in breast milk. Monitor newborns for kernicterus, though sulfapyridine has poor bilirubin-displacing capacity 3
Ignoring drug interactions: Sulfasalazine reduces absorption of folic acid (hence the supplementation requirement) and digoxin 3
Breastfeeding Considerations
Sulfasalazine appears in minimal amounts in breast milk, while sulfapyridine reaches 30-60% of maternal serum levels 3. Monitor breastfed infants for bloody stools or diarrhea, though causality has not been definitively established. The benefits of breastfeeding generally outweigh theoretical risks when the mother requires sulfasalazine 1.
Alternative Options
If sulfasalazine is not tolerated, alternative 5-ASA agents (oral or rectal mesalamine) can be substituted, as these lack the sulfapyridine moiety and are better tolerated 2. These also require folic acid supplementation, though the mechanism differs.